Kamada (KMDA) Receivables (2012 - 2026)
Kamada's (KMDA) quarterly Receivables came in at $44.0 million in Q2 2026, up 14.9% on a YoY basis from $38.3 million in Q2 2025, and little changed quarter-over-quarter from $43.9 million in Q1 2026.
Analysis
Kamada (KMDA) Receivables (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Receivables for 15 consecutive years, with $44.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables rose 14.9% year-over-year to $44.0 million; the trailing twelve-month figure through Jun 2026 stood at $44.0 million (up 14.9% YoY), and the FY2025 full-year result was $34.6 million, up 16.86% from the prior year.
- Receivables was little changed at $44.0 million in Q2 2026 per KMDA's latest filing, from $43.9 million in the prior quarter.
- Across five years, Receivables topped out at $44.0 million in Q2 2026 and bottomed at $20.0 million in Q4 2023.
- Historically, Receivables has averaged $32.0 million across 5 years, with a median of $33.3 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Receivables tumbled 42.55% in 2023, then surged 59.76% in 2025.
- Over 5 years, Receivables stood at $34.8 million in 2022, then sank by 42.55% to $20.0 million in 2023, then gained by 9.01% to $21.8 million in 2024, then jumped by 58.39% to $34.6 million in 2025, then climbed by 27.39% to $44.0 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $44.0 million, $43.9 million, and $34.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 44.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.01 Mn |
| Mar 31, 2026 | 43.94 Mn |
| Dec 31, 2025 | 34.55 Mn |
| Sep 30, 2025 | 39.07 Mn |
| Jun 30, 2025 | 38.31 Mn |
| Mar 31, 2025 | 35.80 Mn |
| Dec 31, 2024 | 21.81 Mn |
| Sep 30, 2024 | 24.45 Mn |
| Jun 30, 2024 | 34.49 Mn |
| Mar 31, 2024 | 27.24 Mn |
| Dec 31, 2023 | 20.01 Mn |
| Sep 30, 2023 | 33.65 Mn |
| Jun 30, 2023 | 32.85 Mn |
| Mar 31, 2023 | 28.68 Mn |
| Dec 31, 2022 | 34.83 Mn |
| Sep 30, 2022 | 31.16 Mn |
| Jun 30, 2022 | 24.10 Mn |
| Mar 31, 2022 | 27.56 Mn |
| Dec 31, 2021 | 40.72 Mn |
| Sep 30, 2021 | 31.54 Mn |